Alipogene tiparvovec

Jump to navigation Jump to search
Alipogene tiparvovec
Clinical data
Trade namesGlybera
AHFS/Drugs.comUK Drug Information
Routes of
Intramuscular injection
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

WikiDoc Resources for Alipogene tiparvovec


Most recent articles on Alipogene tiparvovec

Most cited articles on Alipogene tiparvovec

Review articles on Alipogene tiparvovec

Articles on Alipogene tiparvovec in N Eng J Med, Lancet, BMJ


Powerpoint slides on Alipogene tiparvovec

Images of Alipogene tiparvovec

Photos of Alipogene tiparvovec

Podcasts & MP3s on Alipogene tiparvovec

Videos on Alipogene tiparvovec

Evidence Based Medicine

Cochrane Collaboration on Alipogene tiparvovec

Bandolier on Alipogene tiparvovec

TRIP on Alipogene tiparvovec

Clinical Trials

Ongoing Trials on Alipogene tiparvovec at Clinical

Trial results on Alipogene tiparvovec

Clinical Trials on Alipogene tiparvovec at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alipogene tiparvovec

NICE Guidance on Alipogene tiparvovec


FDA on Alipogene tiparvovec

CDC on Alipogene tiparvovec


Books on Alipogene tiparvovec


Alipogene tiparvovec in the news

Be alerted to news on Alipogene tiparvovec

News trends on Alipogene tiparvovec


Blogs on Alipogene tiparvovec


Definitions of Alipogene tiparvovec

Patient Resources / Community

Patient resources on Alipogene tiparvovec

Discussion groups on Alipogene tiparvovec

Patient Handouts on Alipogene tiparvovec

Directions to Hospitals Treating Alipogene tiparvovec

Risk calculators and risk factors for Alipogene tiparvovec

Healthcare Provider Resources

Symptoms of Alipogene tiparvovec

Causes & Risk Factors for Alipogene tiparvovec

Diagnostic studies for Alipogene tiparvovec

Treatment of Alipogene tiparvovec

Continuing Medical Education (CME)

CME Programs on Alipogene tiparvovec


Alipogene tiparvovec en Espanol

Alipogene tiparvovec en Francais


Alipogene tiparvovec in the Marketplace

Patents on Alipogene tiparvovec

Experimental / Informatics

List of terms related to Alipogene tiparvovec

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]


Alipogene Gene Th.png

Alipogene tiparvovec (marketed under the trade name Glybera) is a gene therapy treatment that compensates for lipoprotein lipase deficiency (LPLD), which can cause severe pancreatitis.[1] In July 2012, the European Medicines Agency recommended it for approval, the first recommendation for a gene therapy treatment in either Europe or the United States. The recommendation was endorsed by the European Commission in November 2012[2][3] and commercial rollout is expected in late 2013.[4]


The adeno-associated virus serotype 1 (AAV1) viral vector delivers an intact copy of the human lipoprotein lipase (LPL) gene. Data from the clinical trials indicates that fat concentrations in blood were reduced between 3 and 12 weeks after injection, in nearly all patients. The advantages of AAV include apparent lack of pathogenicity, delivery to non-dividing cells, and non-integrating in contrast to retroviruses, which show random insertion with accompanying risk of cancer. AAV also presents very low immunogenicity, mainly restricted to generating neutralizing antibodies, and little well defined cytotoxic response.[5][6][7] The cloning capacity of the vector is limited to replacement of the virus's 4.8 kilobase genome.


Alipogene tiparvovec is expected to cost around $1.6 million for treatment[8] which will make it the most expensive medicine in the world.[9]

See Also


  1. European Agency Backs Approval of a Gene Therapy July 20, 2012
  2. Gallagher, James. (2012-11-02) BBC News – Gene therapy: Glybera approved by European Commission. Retrieved on 2012-12-15.
  3. Richards, Sabrina. "Gene Therapy Arrives in Europe". The Scientist. Retrieved 16 November 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  4. Press Release. UniQure (2012-11-02). Retrieved on 2012-12-15.
  5. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (September 1999). "Immune responses to adenovirus and adeno-associated virus in humans". Gene Therapy. 6 (9): 1574–83. doi:10.1038/ PMID 10490767.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  6. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR (1 October 1999). "Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model". Journal of Virology. 73 (10): 8549–58. PMC 112875. PMID 10482608.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  7. Ponnazhagan S, Mukherjee P, Yoder MC; et al. (April 1997). "Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice". Gene. 190 (1): 203–10. doi:10.1016/S0378-1119(96)00576-8. PMID 9185868.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  8. Gene-Therapy Approval Marks Major Milestone
  9. Gene therapy approved in Europe for first time

Template:Lipid modifying agents